2016 American Transplant Congress
Membranoproliferative Glomerulonephritis Pattern without Immunoglobulin and Complement Deposition in Renal Allograft Was Related to the Injury of Antibody-Mediated Rejection.
National Clinical Research Center of Kidney Diseases, Nanjing, China.
Background: Differential diagnosis of Membranoproliferative Glomerulonephritis (MPGN) in renal allograft was difficult because of the confused etiology. Recurrent or de novo MPGN were related to…2016 American Transplant Congress
The Effect of Tocilizmab Treatment (TCZ-Rx) on Total IgG and Anti-CMV-IgG Levels in HLA-Sensitized (HS) Kidney Transplant Patients.
Background: TCZ has anti-B cell and anti-inflammatory properties. We have reported its successful use for pre-transplant (Tx) desensitization (DES) and treatment of ABMR. We also…2016 American Transplant Congress
The Impact of Complement Binding Donor Specific Antibodies in the First Year After Heart Transplantation.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Background: The development of donor specific antibodies (DSA) after heart transplant has been associated with poor outcome. We now have the ability to assess the…2016 American Transplant Congress
Bortezomib Impacts Tenascin mRNA in PBMNCs.
Medical University of South Carolina, Charleston.
Tenascin (TNC) is a gene thought to play a role in the binding of receptors and syndecan binding. Syndecans are signal transmembrane proteins that act…2016 American Transplant Congress
The Effect of Tocilizmab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.
Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplant in HS patients. TCZ has anti-B cell and anti-inflammatory properties. We have reported its…2016 American Transplant Congress
The Early Outcomes of Bortezomib Therapy in Patients with Late Antibody Mediated Rejection in Renal Transplantation.
Although several strategies for treating antibody mediated rejection (AMR) in renal transplants have been investigated, the formation of donor-specific antibodies (DSA) and ongoing AMR contribute…2016 American Transplant Congress
Ameliorating Progression of Allograft Vasculopathy by Targeting the T Follicular Helper Cell Subset.
Department of Surgery, University of Cambridge, Cambridge, United Kingdom.
BACKGROUNDDevelopment of long-lived alloantibody is closely linked with chronic rejection and graft failure. We examined in a murine model of antibody-mediated rejection (AMR) if targeting…2016 American Transplant Congress
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.
U of Cincinnati, Cincinnati; Mayo Clinic Scottsdale, Scottsdale.
Transplant (Transplant) rate is an optimal endpoint in desensitization (DS) trials in HLA sensitized Txp candidates, however, for waitlisted Txp candidates, wait time heterogeneity compromises…2016 American Transplant Congress
Tacrolimus as a Tool for Intracellular Assessment of von Willebrand Factor Production by Activated Human Glomerular Endothelial Cells.
Renal Division, University Health Center (CHU) of Quebec, Laval University, Quebec, QC, Canada.
Background: Von Willebrand factor (vWF) is a prothrombotic mediator stored in intracytoplasmic granules within endothelial cells and is released by endothelial exocytosis, leading to microangiopathic…2016 American Transplant Congress
Elevation of Peripheral IL-6 in Kidney Transplant Recipients with Antibody Mediated Rejection.
University of Wisconsin, Madison.
Background: Despite current therapy, antibody mediated rejection (AMR) remains a major cause of kidney allograft loss. IL-6 is a known survival factor of antibody secreting…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 57
- Next Page »